AI assistant
NovoCure Ltd — Director's Dealing 2023
Mar 3, 2023
31949_dirs_2023-03-03_dae2611a-15f2-457e-b95a-89f5f7f5ec7a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2023-03-02
Reporting Person: Leonard Frank X (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-03-02 | Ordinary Shares | S | 3799.00 | $75.3235 | Disposed | 59296.00 | Direct |
| 2023-03-02 | Ordinary Shares | S | 308.00 | $76.0511 | Disposed | 58988.00 | Direct |
Footnotes
F1: On March 2, 2023 pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 3,799 shares in multiple trades at prices ranging from $74.89 to $75.88. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2: On March 2, 2023 pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 308 shares in multiple trades at prices ranging from $75.95 to $76.14. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.